Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y6S9
UPID:
RPKL1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y6S9; A6NGM9; Q69YT9; Q6ZMQ6; Q96NR9; Q9BSU9
Background:
Ribosomal protein S6 kinase-like 1, encoded by the gene symbol Q9Y6S9, is a member of the protein kinase family. It plays a crucial role in the regulation of cell growth and proliferation through its involvement in the signaling pathways. This kinase is known for its ability to phosphorylate the S6 ribosomal protein, influencing protein synthesis and cellular growth.
Therapeutic significance:
Understanding the role of Ribosomal protein S6 kinase-like 1 could open doors to potential therapeutic strategies. Its pivotal role in cell growth and proliferation pathways makes it a target of interest for developing treatments against diseases characterized by abnormal cell growth.